CD34+ Cell Therapy for Myocardial Perfusion and Apoptosis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for preventing long-term adverse consequences of vascular insufficiency, particularly after myocardial infarction, as they fail to effectively address the expansion of the myocardial infarct area and progression to heart failure.
Innovation Solution
Administration of a potent dose of autologous mononuclear cells enriched for CD34+ cells, which express CXCR-4 and have CXCR-4-mediated chemotactic activity, to stimulate neoangiogenesis and prevent apoptosis in the peri-infarct border zone, thereby improving myocardial perfusion and reducing cardiomyocyte death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for treating vascular insufficiency after myocardial infarction, then standard medical care is provided, but they fail to prevent expansion of the myocardial infarct area and progression to heart failure
Solution Approach 1:
The patent extracts and isolates a specific subpopulation of CD34+ hematopoietic stem cells with CXCR-4-mediated chemotactic activity from the general mononuclear cell population. This extraction allows for targeted delivery of cells with the specific functional property needed to prevent myocardial infarct expansion and heart failure progression, rather than using non-specific cell populations or conventional therapies.
Solution Approach 2:
The patent changes the functional parameters of the cell product by selecting for cells with specific chemotactic activity toward SDF-1. This parameter change ensures that the administered cells have enhanced ability to migrate to and engraft in the ischemic myocardium, thereby improving their effectiveness in preventing adverse remodeling and heart failure progression compared to conventional therapies.
2Reliability
If autologous mononuclear cells enriched for CD34+ cells are administered to stimulate neoangiogenesis, then myocardial perfusion is improved, but the complexity of cell isolation and enrichment increases
Solution Approach 1:
The patent employs functional assessment of chemotactic activity as feedback to guide the cell enrichment process. By testing cells for their ability to migrate toward SDF-1 in vitro, the process ensures that only cells with the desired functional property are selected for administration. This feedback mechanism optimizes the enrichment process to achieve reliable myocardial perfusion improvement while managing complexity through functional quality control.
Solution Approach 2:
The patent utilizes the patient's own autologous mononuclear cells as the therapeutic agent. The body's own cells perform the neoangiogenesis and myocardial repair functions, eliminating the need for allogeneic cell sources or complex synthetic biomaterials. This self-service approach improves myocardial perfusion through biological mechanisms while avoiding the complexities of xenotransplantation or synthetic device implantation.
3Reliability
If potent doses of chemotactic hematopoietic stem cells are administered to prevent apoptosis, then cardiomyocyte death is reduced, but the requirements for cell potency and viability testing increase
Solution Approach 1:
The patent performs preliminary functional testing of cell potency and viability before administration. By assessing chemotactic activity, colony-forming ability, and viability in vitro prior to patient treatment, the process ensures that only potent, viable cells are administered. This preliminary action guarantees reliable prevention of cardiomyocyte apoptosis while managing the difficulty of measurement through pre-screening protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces major adverse cardiac events, including heart failure and arrhythmias, by enhancing cardiac function and reducing the risk of further cardiovascular events.
Implementation Method 1
enriched for CD34+ cells, which further contain a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1
Implementation Method 2
through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone
Data Source
AI summary
The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events.